The current analyst and expert consensus on Blueprint Medicines is Buy with 0 strong sell and 4 strong buy opinions. The current projected target price consensus is 40.5 with 4 analysts opinions. The most common way Blueprint Medicines analysists use to provide recommendation to public is financial statements analysis. Many experts also interview Blueprint Medicines executives and customers to further validate their buy or sell advice. Note, the total number of analysists currently providing their opinion is not significant to determine adequate consensus on Blueprint Medicines. We strongly encourage you to use your own analysis of Blueprint Medicines to validate this buy or sell advice. Blueprint Medicines buy or sell recommendation module provides average expert sentiment on the projected Blueprint Medicines target price to derive its highest and lowest estimates based on projected price volatility of 4.795. Check also Macroaxis Advice on Blueprint Medicines to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the prospective of investor risk tolerance and investment horizon.